Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...1011121314151617181920...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Adverse events:  Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer. (Pubmed Central) -  Jun 3, 2024   
    The AEs were managed with supportive medications, dose interruptions, dose reductions and multidisciplinary care, which allowed the continuation of the treatment. The patient achieved a good partial response and an ongoing PFS of more than 12 months.
  • ||||||||||  Clinical, Journal:  The role of immunotherapy in urological cancers. (Pubmed Central) -  May 31, 2024   
    Considering ongoing randomized clinical trials, immunotherapeutic agents promise to transform the uro-oncology field significantly. In this review, we aimed to summarize the role of immunotherapy in urothelial, renal and prostate cancer in the light of randomized clinical trials.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Review, Journal:  Systemic Therapy for Pancreatic Neuroendocrine Tumors. (Pubmed Central) -  May 31, 2024   
    Several systemic treatment options have been developed over the last four decades, ranging from cytotoxic chemotherapy and octreotide to newer targeted therapies like sunitinib, cabozantinib, and lenvatinib...The optimal sequence of the systemic therapies for the advanced PanNETs depends mainly on the tumor burden, Ki-67 index, and the tempo of the disease. In the end, drawing from ENETS (European Neuroendocrine Tumor Society) and ESMO (European Society for Medical Oncology) guidelines, we propose a working algorithm for the management of advanced PanNETs, not amenable to surgery or liver-directed therapies.
  • ||||||||||  Trial completion date, Trial primary completion date, Adverse events, Metastases:  Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. (clinicaltrials.gov) -  May 31, 2024   
    P4,  N=53, Recruiting, 
    In the end, drawing from ENETS (European Neuroendocrine Tumor Society) and ESMO (European Society for Medical Oncology) guidelines, we propose a working algorithm for the management of advanced PanNETs, not amenable to surgery or liver-directed therapies. Trial completion date: Jun 2024 --> Apr 2025 | Trial primary completion date: May 2024 --> Feb 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Systematic Review of the Efficacy and Safety of Lenvatinib in Various Solid Tumors. (Pubmed Central) -  May 30, 2024   
    Conclusions Lenvatinib in various solid tumors can prolong OS and disease PFS of patients, improve the clinical benefit rate and improve the quality of life of patients. At the same time, there is a certain incidence of adverse events, and symptomatic intervention should be given in clinical medication.
  • ||||||||||  IBI-363 / Innovent Biologics
    Phase classification, Trial completion date, Trial primary completion date, Metastases:  Promise: The Efficacy and Safety of IBI363 in Solid Tumors (clinicaltrials.gov) -  May 30, 2024   
    P1/2,  N=430, Recruiting, 
    Clinical Trial Registration: UMIN000022243. Phase classification: P1 --> P1/2 | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Metastases:  Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. (Pubmed Central) -  May 29, 2024   
    Our findings suggest that rechallenge with lenvatinib after failure of both lenvatinib and sorafenib showed manageable safety and modest efficacy in patients with metastatic thyroid cancer in clinical practice. The strategy of lenvatinib rechallenge may provide an alternative option for patients with no targetable driver genes or when selective kinase inhibitors are not indicated.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal:  Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma. (Pubmed Central) -  May 26, 2024   
    It demonstrates the importance of patient counselling and education regarding treatment options and the rare side effects of treatments. Careful management is warranted for patients with risk factors for exacerbation of PH-related complications; moreover, the effective use of CECT is clinically important.
  • ||||||||||  Review, Journal:  Insights in Molecular Therapies for Hepatocellular Carcinoma. (Pubmed Central) -  May 25, 2024   
    Established and recommended targeted treatment options that already exist for patients are considered for systemic treatment: atezolizumab/bevacizumab, durvalumab/tremelimumab, sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab. Combination treatment for systemic treatment and local ablative treatment or transarterial chemoembolization and adjuvant and neoadjuvant treatment strategies are under clinical investigation.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  The successful posterior sectionectomy accompanied with caudate lobectomy for hepatocellular carcinoma located in segment 1 after LEN-TACE: a case report. (Pubmed Central) -  May 25, 2024   
    We present a successful radical hepatectomy for a large HCC located in segment 1 accompanied with the preoperative Lenvatinib (LEN)-TACE sequential treatment...Histological findings showed the Japan TNM stage III HCC with 70% necrosis. The multi-modal strategy of LEN-TACE followed by radical hepatectomy by confirming downsizing or devascularization in tumor is supposed to be useful and would be a preoperative chemotherapy option, and promising for curative treatment in HCC patients with progressive or large HCC, which may lead to safety by prevention surrounding major vascular injury.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (clinicaltrials.gov) -  May 20, 2024   
    P2,  N=36, Active, not recruiting, 
    It is implicated in forwarding HCC progression and exacerbating TKI resistance through its interaction with the IGF-1R/AKT/SNAIL signaling cascade. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial completion date, Trial initiation date:  bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma (clinicaltrials.gov) -  May 20, 2024   
    P=N/A,  N=30, Recruiting, 
    Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Jun 2025 | Initiation date: Oct 2023 --> May 2024
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC (clinicaltrials.gov) -  May 19, 2024   
    P=N/A,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Jun 2025 | Initiation date: Oct 2023 --> May 2024 Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Sep 2024 --> Jun 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib. (Pubmed Central) -  May 16, 2024   
    High-risk varices were independently associated with Child-Pugh B score (odds ratio [OR]: 2.12; 95% CI: 1.08-4.17, p = 0.03), nPVT (OR: 2.54; 95% CI: 1.40-4.61, p = 0.002), and platelets <150,000/?L (OR: 2.47; 95% CI: 1.35-4.50, p = 0.003). In hepatocellular carcinoma patients treated with lenvatinib, the risk of EGV bleeding was mostly low but significant only in patients with high-risk EGV at baseline.
  • ||||||||||  Retrospective data, Journal, Metastases:  Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis. (Pubmed Central) -  May 16, 2024   
    Phase 3 randomized controlled trials (RCTs) testing TKIs, including sorafenib and lenvatinib, or ICIs reporting overall survival (OS) and progression-free survival (PFS) were included...Atezolizumab plus bevacizumab showed the best net health benefit for OS, compared to durvalumab plus tremelimumab...Atezolizumab plus bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to atezolizumab plus bevacizumab, lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  May 16, 2024   
    P2,  N=52, Active, not recruiting, 
    A combination of low-dose cyclophosphamide with lenvatinib, pembrolizumab, and TACE is safe and effective for uHCC, showcasing a promising therapeutic strategy for managing uHCC. Trial primary completion date: Mar 2024 --> Mar 2025 | Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Mar 2025
  • ||||||||||  Journal, Metastases:  Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. (Pubmed Central) -  May 15, 2024   
    A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis. (Pubmed Central) -  May 15, 2024   
    On the contrary, loss of EVA1A activated the PI3K/AKT/MDM2 signaling pathway and inhibited autophagy, promoting p53 proteasomal degradation and mutant p53 accumulation respectively. These findings establish a crucial role of EVA1A loss in driving lenvatinib resistance involving a mechanism of modulating PI3K/AKT/p53 signaling axis and suggest that upregulating EVA1A is a promising therapeutic strategy for alleviating resistance to lenvatinib, thereby improving the efficacy of HCC treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (clinicaltrials.gov) -  May 15, 2024   
    P2,  N=26, Recruiting, 
    These findings establish a crucial role of EVA1A loss in driving lenvatinib resistance involving a mechanism of modulating PI3K/AKT/p53 signaling axis and suggest that upregulating EVA1A is a promising therapeutic strategy for alleviating resistance to lenvatinib, thereby improving the efficacy of HCC treatment. Trial primary completion date: May 2024 --> Feb 2025
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal:  The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma. (Pubmed Central) -  May 11, 2024   
    Pre-treatment ALBI grade had a significant impact on the decision to accept sequential therapy in patients with progressed HCC. The patients who were able to undergo sequential therapy had a better survival outcome compared to those who received only one agent, and the pre-treatment ALBI level might be regarded as a cornerstone tool to assess survival outcomes in patients undergoing treatment for HCC.